{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:49:08Z","timestamp":1793364548467,"version":"4.5.0"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s11912-025-01645-7","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T05:43:41Z","timestamp":1740030221000},"page":"236-246","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Advancements in the Diagnosis, Treatment, and Risk Stratification of Non-Muscle Invasive Bladder Cancer"],"prefix":"10.1007","volume":"27","author":[{"given":"Shayan","family":"Smani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"DuBois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Sutherland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed N.","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Humphrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hesse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei Shen","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darryl","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soum D.","family":"Lokeshwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fady","family":"Ghali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"key":"1645_CR1","unstructured":"Institute NC. SEER cancer stat facts: bladder cancer. National Cancer Institute Bethesda, MD; 2019."},{"issue":"5","key":"1645_CR2","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1097\/MOU.0000000000000078","volume":"24","author":"M Mossanen","year":"2014","unstructured":"Mossanen M, Gore JL. The burden of bladder cancer care: direct and indirect costs. Curr Opin Urol. 2014;24(5):487\u201391.","journal-title":"Curr Opin Urol"},{"key":"1645_CR3","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s00345-009-0395-z","volume":"27","author":"KD Sievert","year":"2009","unstructured":"Sievert KD, Amend B, Nagele U, Schilling D, Bedke J, Horstmann M, et al. Economic aspects of bladder cancer: what are the benefits and costs? World J Urol. 2009;27:295\u2013300.","journal-title":"World J Urol"},{"key":"1645_CR4","doi-asserted-by":"crossref","unstructured":"Holzbeierlein JM, Bixler BR, Buckley DI, Chang SS, Holmes R, James AC et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline: 2024 amendment. J Urol. 2024:101097.","DOI":"10.1097\/JU.0000000000004452"},{"issue":"2","key":"1645_CR5","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","volume":"63","author":"M Burger","year":"2013","unstructured":"Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63(2):234\u201341.","journal-title":"Eur Urol"},{"key":"1645_CR6","unstructured":"Clinic C. Transitional cell cancer. https:\/\/my.clevelandclinic.org\/health\/diseases\/6239-transitional-cell-cancer (2023). Accessed October 3 2024."},{"key":"1645_CR7","unstructured":"Society AC. Bladder cancer stages. https:\/\/www.cancer.org\/cancer\/types\/bladder-cancer\/detection-diagnosis-staging\/staging.html (2019). Accessed October 10 2024."},{"key":"1645_CR8","doi-asserted-by":"crossref","unstructured":"McGonagle KE, Schroeck FR, Dematt EJ, Mi Z, Biswas K, Among patients with non-muscle invasive, bladder cancer (NMIBC), overall survival is substantially worse than bladder-cancer specific survival: a national va cohort study. Urologic Oncology: Seminars and Original Investigations: Elsevier; 2024. p. S68.","DOI":"10.1016\/j.urolonc.2024.01.195"},{"issue":"12","key":"1645_CR9","doi-asserted-by":"publisher","first-page":"7892","DOI":"10.1245\/s10434-023-14051-9","volume":"30","author":"A \u015alusarczyk","year":"2023","unstructured":"\u015alusarczyk A, Zapa\u0142a P, Zapa\u0142a \u0141, Borkowski T, Radziszewski P. Cancer-Specific Survival of patients with non-muscle-invasive bladder Cancer: a Population-based analysis. Ann Surg Oncol. 2023;30(12):7892\u2013902. https:\/\/doi.org\/10.1245\/s10434-023-14051-9.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"1645_CR10","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","volume":"69","author":"S Cambier","year":"2016","unstructured":"Cambier S, Sylvester RJ, Collette L, Gontero P, Brausi MA, van Andel G, et al. EORTC nomograms and Risk groups for Predicting recurrence, progression, and Disease-specific and overall survival in Non-muscle-invasive Stage Ta-T1 urothelial bladder Cancer patients treated with 1\u20133 years of maintenance Bacillus Calmette-Gu\u00e9rin. Eur Urol. 2016;69(1):60\u20139. https:\/\/doi.org\/10.1016\/j.eururo.2015.06.045.","journal-title":"Eur Urol"},{"issue":"3","key":"1645_CR11","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1097\/ju.0000000000000593","volume":"203","author":"CR Ritch","year":"2020","unstructured":"Ritch CR, Velasquez MC, Kwon D, Becerra MF, Soodana-Prakash N, Atluri VS, et al. Use and Validation of the AUA\/SUO risk grouping for nonmuscle invasive bladder Cancer in a contemporary cohort. J Urol. 2020;203(3):505\u201311. https:\/\/doi.org\/10.1097\/ju.0000000000000593.","journal-title":"J Urol"},{"key":"1645_CR12","doi-asserted-by":"publisher","unstructured":"Badalament RA, Hermansen DK, Kimmel M, Gay H, Herr HW, Fair WR, et al. The sensitivity of bladder wash flow cytometry, bladder wash cytology, and voided cytology in the detection of bladder carcinoma. Cancer. 1987;60(7):1423\u20137. https:\/\/doi.org\/10.1002\/1097-0142(19871001)60:7%3C1423::aid-cncr2820600702%3E3.0.co;2-6.","DOI":"10.1002\/1097-0142(19871001)60:7%3C1423::aid-cncr2820600702%3E3.0.co;2-6"},{"issue":"12","key":"1645_CR13","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1007\/s00345-018-2380-x","volume":"36","author":"F Soria","year":"2018","unstructured":"Soria F, Droller MJ, Lotan Y, Gontero P, D\u2019Andrea D, Gust KM, et al. An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer. World J Urol. 2018;36(12):1981\u201395. https:\/\/doi.org\/10.1007\/s00345-018-2380-x.","journal-title":"World J Urol"},{"issue":"1","key":"1645_CR14","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41392-020-00222-7","volume":"5","author":"Y Xie","year":"2020","unstructured":"Xie Y, Su N, Yang J, Tan Q, Huang S, Jin M, et al. FGF\/FGFR signaling in health and disease. Signal Transduct Target Therapy. 2020;5(1):181.","journal-title":"Signal Transduct Target Therapy"},{"issue":"6","key":"1645_CR15","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/S0092-8674(00)81069-7","volume":"84","author":"C Deng","year":"1996","unstructured":"Deng C, Wynshaw-Boris A, Zhou F, Kuo A, Leder P. Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell. 1996;84(6):911\u201321.","journal-title":"Cell"},{"key":"1645_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12894-018-0373-0","volume":"18","author":"AA Hashmi","year":"2018","unstructured":"Hashmi AA, Hussain ZF, Irfan M, Khan EY, Faridi N, Naqvi H, et al. Prognostic significance of epidermal growth factor receptor (EGFR) over expression in urothelial carcinoma of urinary bladder. BMC Urol. 2018;18:1\u20136.","journal-title":"BMC Urol"},{"issue":"4","key":"1645_CR17","doi-asserted-by":"publisher","first-page":"e751","DOI":"10.1016\/j.clgc.2019.04.008","volume":"17","author":"F Di Maida","year":"2019","unstructured":"Di Maida F, Mari A, Gesolfo CS, Cangemi A, Allegro R, Sforza S, et al. Epidermal growth factor receptor (EGFR) cell expression during adjuvant treatment after transurethral resection for non-muscle-invasive bladder cancer: a new potential tool to identify patients at higher risk of disease progression. Clin Genitourin Cancer. 2019;17(4):e751\u20138.","journal-title":"Clin Genitourin Cancer"},{"issue":"6","key":"1645_CR18","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.eururo.2017.05.032","volume":"72","author":"EJ Pietzak","year":"2017","unstructured":"Pietzak EJ, Bagrodia A, Cha EK, Drill EN, Iyer G, Isharwal S, et al. Next-generation sequencing of nonmuscle invasive bladder cancer reveals potential biomarkers and rational therapeutic targets. Eur Urol. 2017;72(6):952\u20139.","journal-title":"Eur Urol"},{"issue":"1","key":"1645_CR19","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.annonc.2023.09.3116","volume":"35","author":"JWF Catto","year":"2024","unstructured":"Catto JWF, Tran B, Roupr\u00eat M, Gschwend JE, Loriot Y, Nishiyama H, et al. Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer. Ann Oncol. 2024;35(1):98\u2013106. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.3116.","journal-title":"Ann Oncol"},{"key":"1645_CR20","doi-asserted-by":"publisher","first-page":"e07918","DOI":"10.7554\/eLife.07918","volume":"4","author":"K Chiba","year":"2015","unstructured":"Chiba K, Johnson JZ, Vogan JM, Wagner T, Boyle JM, Hockemeyer D. Cancer-associated TERT promoter mutations abrogate telomerase silencing. Elife. 2015;4:e07918.","journal-title":"Elife"},{"issue":"36","key":"1645_CR21","doi-asserted-by":"publisher","first-page":"4203","DOI":"10.1038\/onc.2012.441","volume":"32","author":"Z Liu","year":"2013","unstructured":"Liu Z, Li Q, Li K, Chen L, Li W, Hou M, et al. Telomerase reverse transcriptase promotes epithelial\u2013mesenchymal transition and stem cell-like traits in cancer cells. Oncogene. 2013;32(36):4203\u201313. https:\/\/doi.org\/10.1038\/onc.2012.441.","journal-title":"Oncogene"},{"issue":"4","key":"1645_CR22","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/bjc.2017.210","volume":"117","author":"F Descotes","year":"2017","unstructured":"Descotes F, Kara N, Decaussin-Petrucci M, Piaton E, Geiguer F, Rodriguez-Lafrasse C, et al. Non-invasive prediction of recurrence in bladder cancer by detecting somatic TERT promoter mutations in urine. Br J Cancer. 2017;117(4):583\u20137.","journal-title":"Br J Cancer"},{"issue":"22","key":"1645_CR23","doi-asserted-by":"publisher","first-page":"14319","DOI":"10.3390\/ijms232214319","volume":"23","author":"H Pakmanesh","year":"2022","unstructured":"Pakmanesh H, Anvari O, Forey N, Weiderpass E, Malekpourafshar R, Iranpour M, et al. TERT promoter mutations as simple and non-invasive urinary biomarkers for the detection of urothelial bladder cancer in a high-risk region. Int J Mol Sci. 2022;23(22):14319.","journal-title":"Int J Mol Sci"},{"issue":"17","key":"1645_CR24","doi-asserted-by":"publisher","first-page":"6072","DOI":"10.3390\/ijms21176072","volume":"21","author":"T Hayashi","year":"2020","unstructured":"Hayashi T, Fujita K, Hayashi Y, Hatano K, Kawashima A, McConkey DJ, et al. Mutational landscape and environmental effects in bladder cancer. Int J Mol Sci. 2020;21(17):6072.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"1645_CR25","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.eururo.2016.12.016","volume":"71","author":"E Christensen","year":"2017","unstructured":"Christensen E, Birkenkamp-Demtr\u00f6der K, Nordentoft I, H\u00f8yer S, Van der Keur K, Van Kessel K, et al. Liquid biopsy analysis of FGFR3 and PIK3CA hotspot mutations for disease surveillance in bladder cancer. Eur Urol. 2017;71(6):961\u20139.","journal-title":"Eur Urol"},{"key":"1645_CR26","doi-asserted-by":"publisher","first-page":"643282","DOI":"10.3389\/fimmu.2021.643282","volume":"12","author":"Y-H Pan","year":"2021","unstructured":"Pan Y-H, Zhang J-X, Chen X, Liu F, Cao J-Z, Chen Y, et al. Predictive value of the TP53\/PIK3CA\/ATM mutation classifier for patients with bladder cancer responding to immune checkpoint inhibitor therapy. Front Immunol. 2021;12:643282.","journal-title":"Front Immunol"},{"issue":"10","key":"1645_CR27","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41585-019-0226-y","volume":"16","author":"AK Schneider","year":"2019","unstructured":"Schneider AK, Chevalier MF, Derr\u00e9 L. The multifaceted immune regulation of bladder cancer. Nat Reviews Urol. 2019;16(10):613\u201330.","journal-title":"Nat Reviews Urol"},{"issue":"2","key":"1645_CR28","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/cas.13887","volume":"110","author":"B Wang","year":"2019","unstructured":"Wang B, Pan W, Yang M, Yang W, He W, Chen X, et al. Programmed death ligand-1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder. Cancer Sci. 2019;110(2):489\u201398.","journal-title":"Cancer Sci"},{"issue":"11","key":"1645_CR29","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S1471-4906(02)02302-5","volume":"23","author":"A Mantovani","year":"2002","unstructured":"Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23(11):549\u201355.","journal-title":"Trends Immunol"},{"issue":"8","key":"1645_CR30","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1172\/JCI89717","volume":"127","author":"MF Chevalier","year":"2017","unstructured":"Chevalier MF, Trabanelli S, Racle J, Salom\u00e9 B, Cesson V, Gharbi D, et al. ILC2-modulated T cell\u2013to-MDSC balance is associated with bladder cancer recurrence. J Clin Investig. 2017;127(8):2916\u201329.","journal-title":"J Clin Investig"},{"issue":"5","key":"1645_CR31","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.eururo.2018.06.045","volume":"74","author":"MF Chevalier","year":"2018","unstructured":"Chevalier MF, Schneider AK, Cesson V, Dartiguenave F, Lucca I, Jichlinski P, et al. Conventional and PD-L1-expressing regulatory T cells are enriched during BCG therapy and may limit its efficacy. Eur Urol. 2018;74(5):540\u20134.","journal-title":"Eur Urol"},{"issue":"3","key":"1645_CR32","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrurol.2014.15","volume":"11","author":"G Redelman-Sidi","year":"2014","unstructured":"Redelman-Sidi G, Glickman MS, Bochner BH. The mechanism of action of BCG therapy for bladder cancer\u2014a current perspective. Nat Reviews Urol. 2014;11(3):153\u201362. https:\/\/doi.org\/10.1038\/nrurol.2014.15.","journal-title":"Nat Reviews Urol"},{"issue":"1","key":"1645_CR33","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk M, Burger M, Capoun O, Cohen D, Comp\u00e9rat EM, Dominguez Escrig JL, et al. European Association of Urology Guidelines on non-muscle-invasive bladder Cancer (Ta, T1, and carcinoma in situ). Eur Urol. 2022;81(1):75\u201394. https:\/\/doi.org\/10.1016\/j.eururo.2021.08.010.","journal-title":"Eur Urol"},{"issue":"7","key":"1645_CR34","first-page":"1762","volume":"47","author":"TL Ratliff","year":"1987","unstructured":"Ratliff TL, Palmer JO, McGarr JA, Brown EJ. Intravesical Bacillus Calmette-Gu\u00e9rin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Gu\u00e9rin. Cancer Res. 1987;47(7):1762\u20136.","journal-title":"Cancer Res"},{"issue":"6","key":"1645_CR35","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1016\/s0022-5347(17)38622-6","volume":"145","author":"MJ Becich","year":"1991","unstructured":"Becich MJ, Carroll S, Ratliff TL. Internalization of Bacille Calmette-Guerin by bladder tumor cells. J Urol. 1991;145(6):1316\u201324. https:\/\/doi.org\/10.1016\/s0022-5347(17)38622-6.","journal-title":"J Urol"},{"issue":"1","key":"1645_CR36","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1046\/j.1365-2249.1999.00756.x","volume":"115","author":"K Taniguchi","year":"1999","unstructured":"Taniguchi K, Koga S, Nishikido M, Yamashita S, Sakuragi T, Kanetake H, et al. Systemic immune response after intravesical instillation of bacille Calmette-Gu\u00e9rin (BCG) for superficial bladder cancer. Clin Exp Immunol. 1999;115(1):131\u20135. https:\/\/doi.org\/10.1046\/j.1365-2249.1999.00756.x.","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"1645_CR37","first-page":"158","volume":"68","author":"D Morton","year":"1970","unstructured":"Morton D, Eilber FR, Malmgren RA, Wood WC. Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery. 1970;68(1):158\u201363. discussion 63\u2013\u20094.","journal-title":"Surgery"},{"key":"1645_CR38","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/nrurol.2017.16","volume":"14","author":"AM Kamat","year":"2017","unstructured":"Kamat AM, Colombel M, Sundi D, Lamm D, Boehle A, Brausi M, et al. BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG. Nat Reviews Urol. 2017;14:244.","journal-title":"Nat Reviews Urol"},{"issue":"7","key":"1645_CR39","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/s1470-2045(21)00147-9","volume":"22","author":"AV Balar","year":"2021","unstructured":"Balar AV, Kamat AM, Kulkarni GS, Uchio EM, Boormans JL, Roumigui\u00e9 M, et al. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol. 2021;22(7):919\u201330. https:\/\/doi.org\/10.1016\/s1470-2045(21)00147-9.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1645_CR40","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1097\/ju.0000000000004020","volume":"212","author":"VM Narayan","year":"2024","unstructured":"Narayan VM, Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, et al. Efficacy of Intravesical Nadofaragene Firadenovec for patients with Bacillus Calmette-Gu\u00e9rin-Unresponsive nonmuscle-invasive bladder Cancer: 5-Year Follow-Up from a phase 3 trial. J Urol. 2024;212(1):74\u201386. https:\/\/doi.org\/10.1097\/ju.0000000000004020.","journal-title":"J Urol"},{"issue":"1","key":"1645_CR41","doi-asserted-by":"publisher","first-page":"EVIDoa2200167","DOI":"10.1056\/EVIDoa2200167","volume":"2","author":"K Chamie","year":"2023","unstructured":"Chamie K, Chang SS, Kramolowsky E, Gonzalgo ML, Agarwal PK, Bassett JC, et al. IL-15 superagonist NAI in BCG-Unresponsive non-muscle-invasive bladder Cancer. NEJM Evid. 2023;2(1):EVIDoa2200167. https:\/\/doi.org\/10.1056\/EVIDoa2200167.","journal-title":"NEJM Evid"},{"issue":"1","key":"1645_CR42","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.eururo.2018.09.005","volume":"75","author":"WS Tan","year":"2019","unstructured":"Tan WS, Panchal A, Buckley L, Devall AJ, Loubi\u00e8re LS, Pope AM, et al. Radiofrequency-induced Thermo-chemotherapy Effect Versus a second course of Bacillus Calmette-Gu\u00e9rin or institutional standard in patients with recurrence of non-muscle-invasive bladder Cancer following induction or maintenance Bacillus Calmette-Gu\u00e9rin therapy (HYMN): a phase III, Open-label, Randomised Controlled Trial. Eur Urol. 2019;75(1):63\u201371. https:\/\/doi.org\/10.1016\/j.eururo.2018.09.005.","journal-title":"Eur Urol"},{"key":"1645_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.08.001","author":"R Li","year":"2024","unstructured":"Li R, Hensley PJ, Gupta S, Al-Ahmadie H, Babjuk M, Black PC, et al. Bladder-sparing therapy for Bacillus Calmette-Gu\u00e9rin\u2013unresponsive non\u2013muscle-invasive bladder Cancer: international bladder Cancer Group recommendations for optimal sequencing and patient selection. Eur Urol. 2024. https:\/\/doi.org\/10.1016\/j.eururo.2024.08.001.","journal-title":"Eur Urol"},{"key":"1645_CR44","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ctrv.2016.05.002","volume":"47","author":"WS Tan","year":"2016","unstructured":"Tan WS, Rodney S, Lamb B, Feneley M, Kelly J. Management of non-muscle invasive bladder cancer: a comprehensive analysis of guidelines from the United States, Europe and Asia. Cancer Treat Rev. 2016;47:22\u201331. https:\/\/doi.org\/10.1016\/j.ctrv.2016.05.002.","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"1645_CR45","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.euo.2022.05.005","volume":"5","author":"WS Tan","year":"2022","unstructured":"Tan WS, Steinberg G, Witjes JA, Li R, Shariat SF, Roupret M, et al. Intermediate-risk non-muscle-invasive bladder Cancer: updated Consensus Definition and Management recommendations from the international bladder Cancer Group. Eur Urol Oncol. 2022;5(5):505\u201316. https:\/\/doi.org\/10.1016\/j.euo.2022.05.005.","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"1645_CR46","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1089\/heq.2018.0004","volume":"2","author":"NH Patel","year":"2018","unstructured":"Patel NH, Bloom J, Hillelsohn J, Fullerton S, Allman D, Matthews G, et al. Prostate Cancer Screening Trends after United States Preventative Services Task Force Guidelines in an Underserved Population. Health Equity. 2018;2(1):55\u201361. https:\/\/doi.org\/10.1089\/heq.2018.0004.","journal-title":"Health Equity"},{"key":"1645_CR47","doi-asserted-by":"crossref","unstructured":"Gontero P, Birtle A, Capoun O, Comp\u00e9rat E, Dominguez-Escrig JL, Liedberg F et al. European Association of Urology guidelines on non\u2013muscle-invasive bladder cancer (TaT1 and carcinoma in situ)\u2014a summary of the 2024 guidelines update. Eur Urol. 2024.","DOI":"10.1016\/j.eururo.2024.07.027"},{"issue":"3","key":"1645_CR48","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.eururo.2013.06.009","volume":"64","author":"N Perlis","year":"2013","unstructured":"Perlis N, Zlotta AR, Beyene J, Finelli A, Fleshner NE, Kulkarni GS. Immediate post\u2013transurethral resection of bladder tumor intravesical chemotherapy prevents non\u2013muscle-invasive bladder cancer recurrences: an updated meta-analysis on 2548 patients and quality-of-evidence review. Eur Urol. 2013;64(3):421\u201330.","journal-title":"Eur Urol"},{"key":"1645_CR49","doi-asserted-by":"publisher","unstructured":"Sylvester RJ, Oosterlinck W, Holmang S, Sydes MR, Birtle A, Gudjonsson S, et al. Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral. Resection with Transurethral Resection Alone in Patients with Stage pTa\u2013pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation? Eur Urol. 2016;69(2):231\u201344. https:\/\/doi.org\/10.1016\/j.eururo.2015.05.050.","DOI":"10.1016\/j.eururo.2015.05.050"},{"issue":"18","key":"1645_CR50","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1001\/jama.2018.4657","volume":"319","author":"EM Messing","year":"2018","unstructured":"Messing EM, Tangen CM, Lerner SP, Sahasrabudhe DM, Koppie TM, Wood DP, et al. Effect of intravesical instillation of gemcitabine vs saline immediately following resection of suspected low-grade non\u2013muscle-invasive bladder cancer on tumor recurrence: SWOG S0337 randomized clinical trial. JAMA. 2018;319(18):1880\u20138.","journal-title":"JAMA"},{"issue":"2","key":"1645_CR51","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1016\/j.clgc.2019.09.005","volume":"18","author":"W Fukuokaya","year":"2020","unstructured":"Fukuokaya W, Kimura T, Miki J, Kimura S, Watanabe H, Bo F, et al. Effectiveness of Intravesical Doxorubicin immediately following Resection of Primary non\u2013muscle-invasive bladder Cancer: a propensity score-matched analysis. Clin Genitourin Cancer. 2020;18(2):e55\u201361.","journal-title":"Clin Genitourin Cancer"},{"key":"1645_CR52","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s00345-018-2196-8","volume":"36","author":"R Tanimoto","year":"2018","unstructured":"Tanimoto R, Saika T, Ebara S, Kobayashi Y, Nasu R, Yamada D, et al. Prospective randomized controlled trial of postoperative early intravesical chemotherapy with pirarubicin (THP) for solitary non-muscle invasive bladder cancer comparing single and two-time instillation. World J Urol. 2018;36:889\u201395.","journal-title":"World J Urol"},{"issue":"2 Pt 1","key":"1645_CR53","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1097\/01.ju.0000076621.71247.6c","volume":"170","author":"MS Soloway","year":"2003","unstructured":"Soloway MS, Bruck DS, Kim SS. Expectant management of small, recurrent, noninvasive papillary bladder tumors. J Urol. 2003;170(2 Pt 1):438\u201341. https:\/\/doi.org\/10.1097\/01.ju.0000076621.71247.6c.","journal-title":"J Urol"},{"issue":"2","key":"1645_CR54","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.euo.2021.05.002","volume":"5","author":"R Contieri","year":"2022","unstructured":"Contieri R, Paciotti M, Lughezzani G, Buffi NM, Frego N, Diana P, et al. Long-term follow-up and Factors Associated with active surveillance failure for patients with non-muscle-invasive bladder Cancer: the bladder Cancer Italian active surveillance (BIAS) experience. Eur Urol Oncol. 2022;5(2):251\u20135. https:\/\/doi.org\/10.1016\/j.euo.2021.05.002.","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"1645_CR55","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.eururo.2007.08.015","volume":"53","author":"JA Witjes","year":"2008","unstructured":"Witjes JA, Hendricksen K. Intravesical pharmacotherapy for non\u2013muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results. Eur Urol. 2008;53(1):45\u201352.","journal-title":"Eur Urol"},{"issue":"2","key":"1645_CR56","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.euf.2021.03.016","volume":"8","author":"E Laukhtina","year":"2022","unstructured":"Laukhtina E, Abufaraj M, Al-Ani A, Ali MR, Mori K, Moschini M, et al. Intravesical therapy in patients with intermediate-risk non\u2013muscle-invasive bladder cancer: a systematic review and network meta-analysis of disease recurrence. Eur Urol Focus. 2022;8(2):447\u201356.","journal-title":"Eur Urol Focus"},{"issue":"4","key":"1645_CR57","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/bju.16371","volume":"134","author":"E Laukhtina","year":"2024","unstructured":"Laukhtina E, Gontero P, Babjuk M, Moschini M, Teoh JY-C, Roupr\u00eat M, et al. Adjuvant intravesical therapy in intermediate-risk non-muscle-invasive bladder cancer. BJU Int. 2024;134(4):644\u201351. https:\/\/doi.org\/10.1111\/bju.16371.","journal-title":"BJU Int"},{"issue":"4","key":"1645_CR58","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.eururo.2008.01.015","volume":"53","author":"RJ Sylvester","year":"2008","unstructured":"Sylvester RJ, Oosterlinck W, Witjes JA. The schedule and duration of intravesical chemotherapy in patients with non\u2013muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials. Eur Urol. 2008;53(4):709\u201319.","journal-title":"Eur Urol"},{"issue":"6","key":"1645_CR59","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/j.euo.2024.06.004","volume":"7","author":"F Soria","year":"2024","unstructured":"Soria F, Rosazza M, Livoti S, Moschini M, De Angelis M, Giudice FD, et al. Clinical validation of the Intermediate-risk non-muscle-invasive bladder Cancer Scoring System and Substratification Model proposed by the international bladder Cancer Group: a Multicenter Young Academic urologists Urothelial Working Group collaboration. Eur Urol Oncol. 2024;7(6):1497\u2013503. https:\/\/doi.org\/10.1016\/j.euo.2024.06.004.","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"1645_CR60","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","volume":"56","author":"P-U Malmstr\u00f6m","year":"2009","unstructured":"Malmstr\u00f6m P-U, Sylvester RJ, Crawford DE, Friedrich M, Krege S, Rintala E, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Gu\u00e9rin for non\u2013muscle-invasive bladder cancer. Eur Urol. 2009;56(2):247\u201356.","journal-title":"Eur Urol"},{"issue":"3","key":"1645_CR61","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1046\/j.1464-410x.2001.02306.x","volume":"88","author":"M Shelley","year":"2001","unstructured":"Shelley M, Kynaston H, Court J, Wilt T, Coles B, Burgon K, et al. A systematic review of intravesical bacillus Calmette-Gu\u00e9rin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int. 2001;88(3):209\u201316.","journal-title":"BJU Int"},{"issue":"6","key":"1645_CR62","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.urology.2005.12.014","volume":"67","author":"RF Han","year":"2006","unstructured":"Han RF, Pan JG. Can intravesical bacillus Calmette-Gu\u00e9rin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology. 2006;67(6):1216\u201323.","journal-title":"Urology"},{"issue":"5","key":"1645_CR63","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","volume":"168","author":"RJ Sylvester","year":"2002","unstructured":"Sylvester RJ, van der MEIJDEN AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002;168(5):1964\u201370.","journal-title":"J Urol"},{"issue":"5","key":"1645_CR64","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","volume":"57","author":"RJ Sylvester","year":"2010","unstructured":"Sylvester RJ, Brausi MA, Kirkels WJ, Hoeltl W, Da Silva FC, Powell PH, et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus Isoniazid in patients with intermediate-and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol. 2010;57(5):766\u201373.","journal-title":"Eur Urol"},{"issue":"2","key":"1645_CR65","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.eururo.2015.06.023","volume":"69","author":"AM Kamat","year":"2016","unstructured":"Kamat AM, Briggman J, Urbauer DL, Svatek R, Nogueras Gonz\u00e1lez GM, Anderson R, et al. Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of changes in urinary cytokine levels predicts patient response to Bacillus Calmette-Gu\u00e9rin. Eur Urol. 2016;69(2):197\u2013200. https:\/\/doi.org\/10.1016\/j.eururo.2015.06.023.","journal-title":"Eur Urol"},{"issue":"3","key":"1645_CR66","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","volume":"63","author":"J Oddens","year":"2013","unstructured":"Oddens J, Brausi M, Sylvester R, Bono A, van de Beek C, van Andel G, et al. Final results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Gu\u00e9rin in Intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose Versus full dose and 1 year Versus 3 years of maintenance. Eur Urol. 2013;63(3):462\u201372. https:\/\/doi.org\/10.1016\/j.eururo.2012.10.039.","journal-title":"Eur Urol"},{"issue":"4","key":"1645_CR67","doi-asserted-by":"publisher","first-page":"887","DOI":"10.3390\/cancers14040887","volume":"14","author":"F Del Giudice","year":"2022","unstructured":"Del Giudice F, Flammia RS, Chung BI, Moschini M, Pradere B, Mari A, et al. Compared efficacy of adjuvant intravesical BCG-TICE vs. BCG-RIVM for high-risk non-muscle invasive bladder cancer (NMIBC): a propensity score matched analysis. Cancers. 2022;14(4):887.","journal-title":"Cancers"},{"key":"1645_CR68","doi-asserted-by":"publisher","unstructured":"Shang PF, Kwong J, Wang ZP, Tian J, Jiang L, Yang K et al. Intravesical Bacillus Calmette-Gu\u00e9rin versus epirubicin for Ta and T1 bladder cancer. Cochrane Database Syst Reviews. 2011(5). https:\/\/doi.org\/10.1002\/14651858.CD006885.pub2","DOI":"10.1002\/14651858.CD006885.pub2"},{"issue":"5","key":"1645_CR69","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.eururo.2020.04.066","volume":"78","author":"MO Grimm","year":"2020","unstructured":"Grimm MO, van der Heijden AG, Colombel M, Muilwijk T, Mart\u00ednez-Pi\u00f1eiro L, Babjuk MM, et al. Treatment of high-grade non-muscle-invasive bladder carcinoma by Standard Number and Dose of BCG instillations Versus reduced number and Standard Dose of BCG Instillations: results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial NIMBUS. Eur Urol. 2020;78(5):690\u20138. https:\/\/doi.org\/10.1016\/j.eururo.2020.04.066.","journal-title":"Eur Urol"},{"issue":"1","key":"1645_CR70","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3233\/blc-150008","volume":"1","author":"RL Steinberg","year":"2015","unstructured":"Steinberg RL, Thomas LJ, O\u2019Donnell MA, Nepple KG. Sequential Intravesical Gemcitabine and Docetaxel for the Salvage treatment of non-muscle invasive bladder Cancer. Bladder Cancer. 2015;1(1):65\u201372. https:\/\/doi.org\/10.3233\/blc-150008.","journal-title":"Bladder Cancer"},{"issue":"1","key":"1645_CR71","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.urolonc.2021.03.024","volume":"40","author":"RL Steinberg","year":"2022","unstructured":"Steinberg RL, Packiam VT, Thomas LJ, Brooks N, Vitale A, Mott SL, et al. Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG. Urol Oncol. 2022;40(1):9. https:\/\/doi.org\/10.1016\/j.urolonc.2021.03.024.","journal-title":"Urol Oncol"},{"issue":"3","key":"1645_CR72","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/mou.0000000000001065","volume":"33","author":"T Kawada","year":"2023","unstructured":"Kawada T, Yanagisawa T, Araki M, Pradere B, Shariat SF. Sequential intravesical gemcitabine and docetaxel therapy in patients with nonmuscle invasive bladder cancer: a systematic review and meta-analysis. Curr Opin Urol. 2023;33(3):211\u20138. https:\/\/doi.org\/10.1097\/mou.0000000000001065.","journal-title":"Curr Opin Urol"},{"issue":"2","key":"1645_CR73","doi-asserted-by":"publisher","first-page":"e230849","DOI":"10.1001\/jamanetworkopen.2023.0849","volume":"6","author":"IM McElree","year":"2023","unstructured":"McElree IM, Steinberg RL, Mott SL, O\u2019Donnell MA, Packiam VT. Comparison of Sequential Intravesical Gemcitabine and Docetaxel vs Bacillus Calmette-Gu\u00e9rin for the treatment of patients with High-Risk non\u2013muscle-invasive bladder Cancer. JAMA Netw Open. 2023;6(2):e230849\u2013e. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.0849.","journal-title":"JAMA Netw Open"},{"key":"1645_CR74","doi-asserted-by":"crossref","unstructured":"Kates M, Chu X, Hahn N, Pietzak E, Smith A, Shevrin DH, et al. Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Gu\u00e9rin(BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-na\u00efve High-grade Non\u2013muscle-invasive Bladder Cancer (BRIDGE). European Urology Focus. 2023;9(4):561-3.doi: 10.1016\/j.euf.2023.06.006.","DOI":"10.1016\/j.euf.2023.06.006"},{"issue":"3","key":"1645_CR75","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1200\/jco.20.01665","volume":"39","author":"JWF Catto","year":"2021","unstructured":"Catto JWF, Gordon K, Collinson M, Poad H, Twiddy M, Johnson M, et al. Radical Cystectomy Against Intravesical BCG for High-Risk High-Grade nonmuscle invasive bladder Cancer: results from the Randomized controlled BRAVO-Feasibility study. J Clin Oncol. 2021;39(3):202\u201314. https:\/\/doi.org\/10.1200\/jco.20.01665.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1645_CR76","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.eururo.2009.09.024","volume":"57","author":"HM Fritsche","year":"2010","unstructured":"Fritsche HM, Burger M, Svatek RS, Jeldres C, Karakiewicz PI, Novara G, et al. Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur Urol. 2010;57(2):300\u20139. https:\/\/doi.org\/10.1016\/j.eururo.2009.09.024.","journal-title":"Eur Urol"},{"issue":"4","key":"1645_CR77","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/bju.13146","volume":"117","author":"M Moschini","year":"2016","unstructured":"Moschini M, Sharma V, Dell\u2019Oglio P, Cucchiara V, Gandaglia G, Cantiello F, et al. Comparing long-term outcomes of primary and progressive carcinoma invading bladder muscle after radical cystectomy. BJU Int. 2016;117(4):604\u201310.","journal-title":"BJU Int"},{"key":"1645_CR78","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s00345-009-0402-4","volume":"27","author":"RE Hautmann","year":"2009","unstructured":"Hautmann RE, Volkmer BG, Gust K. Quantification of the survival benefit of early versus deferred cystectomy in high-risk non-muscle invasive bladder cancer (T1 G3). World J Urol. 2009;27:347\u201351.","journal-title":"World J Urol"},{"issue":"3","key":"1645_CR79","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.eururo.2014.01.029","volume":"66","author":"JJ Leow","year":"2014","unstructured":"Leow JJ, Reese SW, Jiang W, Lipsitz SR, Bellmunt J, Trinh Q-D, et al. Propensity-matched comparison of morbidity and costs of open and robot-assisted radical cystectomies: a contemporary population-based analysis in the United States. Eur Urol. 2014;66(3):569\u201376.","journal-title":"Eur Urol"},{"issue":"4","key":"1645_CR80","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/j.juro.2010.06.007","volume":"184","author":"C Stimson","year":"2010","unstructured":"Stimson C, Chang SS, Barocas DA, Humphrey JE, Patel SG, Clark PE, et al. Early and late perioperative outcomes following radical cystectomy: 90-day readmissions, morbidity and mortality in a contemporary series. J Urol. 2010;184(4):1296\u2013300.","journal-title":"J Urol"},{"issue":"21","key":"1645_CR81","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1001\/jama.2022.7393","volume":"327","author":"JWF Catto","year":"2022","unstructured":"Catto JWF, Khetrapal P, Ricciardi F, Ambler G, Williams NR, Al-Hammouri T, et al. Effect of Robot-assisted Radical Cystectomy with Intracorporeal urinary diversion vs Open Radical Cystectomy on 90-Day morbidity and mortality among patients with bladder Cancer: a Randomized Clinical Trial. JAMA. 2022;327(21):2092\u2013103. https:\/\/doi.org\/10.1001\/jama.2022.7393.","journal-title":"JAMA"},{"issue":"1","key":"1645_CR82","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/bju.15505","volume":"129","author":"M Abozaid","year":"2022","unstructured":"Abozaid M, Tan WS, Khetrapal P, Baker H, Duncan J, Sridhar A, et al. Recovery of health-related quality of life in patients undergoing robot\u2010assisted radical cystectomy with intracorporeal diversion. BJU Int. 2022;129(1):72\u20139.","journal-title":"BJU Int"},{"issue":"3","key":"1645_CR83","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","volume":"19","author":"JP Stein","year":"2001","unstructured":"Stein JP, Lieskovsky G, Cote R, Groshen S, Feng A-C, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19(3):666\u201375.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1645_CR84","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/S0022-5347(05)65756-4","volume":"166","author":"HW Herr","year":"2001","unstructured":"Herr HW, Sogani PC. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol. 2001;166(4):1296\u20139.","journal-title":"J Urol"},{"issue":"6","key":"1645_CR85","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1016\/j.juro.2016.01.087","volume":"195","author":"CR Haas","year":"2016","unstructured":"Haas CR, Barlow LJ, Badalato GM, DeCastro GJ, Benson MC, McKiernan JM. The timing of radical cystectomy for bacillus Calmette-Guerin failure: comparison of outcomes and risk factors for prognosis. J Urol. 2016;195(6):1704\u20139.","journal-title":"J Urol"},{"key":"1645_CR86","doi-asserted-by":"publisher","DOI":"10.1097\/mou.0000000000001213","author":"L Xia","year":"2024","unstructured":"Xia L, Daneshmand S. Does radical cystectomy still have a role in BCG-unresponsive nonmuscle invasive bladder cancer? Curr Opin Urol. 2024. https:\/\/doi.org\/10.1097\/mou.0000000000001213.","journal-title":"Curr Opin Urol"},{"issue":"1","key":"1645_CR87","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/s1470-2045(20)30540-4","volume":"22","author":"SA Boorjian","year":"2021","unstructured":"Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, et al. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 2021;22(1):107\u201317. https:\/\/doi.org\/10.1016\/s1470-2045(20)30540-4.","journal-title":"Lancet Oncol"},{"issue":"10","key":"1645_CR88","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/s41585-023-00789-0","volume":"20","author":"WS Tan","year":"2023","unstructured":"Tan WS, Hall E, Kamat AM, Kelly JD. Clinical trial design for non-muscle-invasive bladder cancer. Nat Reviews Urol. 2023;20(10):575\u20136. https:\/\/doi.org\/10.1038\/s41585-023-00789-0.","journal-title":"Nat Reviews Urol"},{"issue":"8","key":"1645_CR89","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1016\/j.urolonc.2012.04.010","volume":"31","author":"CP Dinney","year":"2013","unstructured":"Dinney CP, Greenberg RE, Steinberg GD. Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Gu\u00e9rin. Urol Oncol. 2013;31(8):1635\u201342. https:\/\/doi.org\/10.1016\/j.urolonc.2012.04.010.","journal-title":"Urol Oncol"},{"issue":"3","key":"1645_CR90","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/S0022-5347(05)67799-3","volume":"163","author":"G Steinberg","year":"2000","unstructured":"Steinberg G, Bahnson R, Brosman S, Middleton R, Wajsman Z, Wehle M, et al. Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. J Urol. 2000;163(3):761\u20137.","journal-title":"J Urol"},{"issue":"5","key":"1645_CR91","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1097\/JU.0000000000002848","volume":"208","author":"IM McElree","year":"2022","unstructured":"McElree IM, Packiam VT, Steinberg RL, Mott SL, Gellhaus PT, Nepple KG, et al. Sequential intravesical valrubicin and docetaxel for the salvage treatment of non\u2013muscle-invasive bladder cancer. J Urol. 2022;208(5):969\u201377.","journal-title":"J Urol"},{"issue":"2","key":"1645_CR92","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.urology.2013.10.030","volume":"83","author":"JP Jarow","year":"2014","unstructured":"Jarow JP, Lerner SP, Kluetz PG, Liu K, Sridhara R, Bajorin D, et al. Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association public workshop. Urology. 2014;83(2):262\u20134. https:\/\/doi.org\/10.1016\/j.urology.2013.10.030.","journal-title":"Urology"},{"key":"1645_CR93","doi-asserted-by":"crossref","unstructured":"Vilaseca A, Guerrero F, Zainfeld D, Shore ND, Rodriguez Faba O, Meijer RP, et al. Safety and efficacy of the erdafitinib (erda) intravesical delivery system, TAR-210, in patients (pts) with non\u2013muscle-invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC) harboring select FGFR mutations or fusions: phase 1 first-in-human study. American Society of Clinical Oncology; 2023.","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS583"},{"key":"1645_CR94","doi-asserted-by":"publisher","first-page":"v380","DOI":"10.1093\/annonc\/mdz249.041","volume":"30","author":"V Weyerer","year":"2019","unstructured":"Weyerer V, Stoehr R, Juette H, Wirtz R, Eckstein M, Roghmann F, et al. Evaluation of different diagnostic methods for identification of FGFR alteration in advanced urothelial carcinomas: proficiency results based on multiple RNA extraction kits and mutation detection methods. Ann Oncol. 2019;30:v380.","journal-title":"Ann Oncol"},{"issue":"10","key":"1645_CR95","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.urolonc.2017.07.005","volume":"36","author":"VT Packiam","year":"2018","unstructured":"Packiam VT, Lamm DL, Barocas DA, Trainer A, Fand B, Davis RL, et al. An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non\u2013muscle-invasive bladder cancer: interim results. Urologic Oncology: Seminars Original Investigations. 2018;36(10):440\u20137. https:\/\/doi.org\/10.1016\/j.urolonc.2017.07.005.","journal-title":"Urologic Oncology: Seminars Original Investigations"},{"issue":"6suppl","key":"1645_CR96","doi-asserted-by":"publisher","first-page":"TPS593","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS593","volume":"40","author":"MSVD Heijden","year":"2022","unstructured":"Heijden MSVD, Cutie C, Hampras S, Indoria C, Stewart R, Acharya M, et al. SunRISe-1: phase 2b study of TAR-200 plus cetrelimab, TAR-200 alone, or cetrelimab alone in participants with high-risk nonmuscle-invasive bladder cancer unresponsive to Bacillus Calmette-Gu\u00e9rin who are ineligible for or decline radical cystectomy. J Clin Oncol. 2022;40(6suppl):TPS593\u2013TPS. https:\/\/doi.org\/10.1200\/JCO.2022.40.6_suppl.TPS593.","journal-title":"J Clin Oncol"},{"key":"1645_CR97","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3233\/BLC-230056","volume":"9","author":"E Chang","year":"2023","unstructured":"Chang E, Hahn NM, Lerner SP, Fallah J, Agrawal S, Kamat AM, et al. Advancing clinical Trial Design for non-muscle invasive bladder Cancer. Bladder Cancer. 2023;9:271\u201386. https:\/\/doi.org\/10.3233\/BLC-230056.","journal-title":"Bladder Cancer"},{"issue":"2","key":"1645_CR98","doi-asserted-by":"publisher","first-page":"964","DOI":"10.3390\/ijms24020964","volume":"24","author":"S Das","year":"2023","unstructured":"Das S, Hayden J, Sullivan T, Rieger-Christ K. The roles of miRNAs in predicting bladder cancer recurrence and resistance to treatment. Int J Mol Sci. 2023;24(2):964.","journal-title":"Int J Mol Sci"},{"key":"1645_CR99","doi-asserted-by":"publisher","first-page":"657483","DOI":"10.3389\/fonc.2021.657483","volume":"11","author":"J Zhang","year":"2021","unstructured":"Zhang J, Dai D, Tian J, Li L, Bai J, Xu Y, et al. Circulating tumor DNA analyses predict disease recurrence in non-muscle-invasive bladder cancer. Front Oncol. 2021;11:657483.","journal-title":"Front Oncol"},{"issue":"16","key":"1645_CR100","doi-asserted-by":"publisher","first-page":"4599","DOI":"10.1158\/1078-0432.CCR-21-0205","volume":"27","author":"JS Damrauer","year":"2021","unstructured":"Damrauer JS, Roell KR, Smith MA, Sun X, Kirk EL, Hoadley KA, et al. Identification of a novel inflamed tumor microenvironment signature as a predictive biomarker of bacillus Calmette-Gu\u00e9rin immunotherapy in non\u2013muscle-invasive bladder cancer. Clin Cancer Res. 2021;27(16):4599\u2013609.","journal-title":"Clin Cancer Res"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-025-01645-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-025-01645-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-025-01645-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T14:36:48Z","timestamp":1743691008000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-025-01645-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":100,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["1645"],"URL":"https:\/\/doi.org\/10.1007\/s11912-025-01645-7","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,20]]},"assertion":[{"value":"27 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All reported studies with human subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional\/national research committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}